The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unm...

Descripción completa

Detalles Bibliográficos
Autores principales: Conforti, Franco, Davies, Elizabeth R., Calderwood, Claire J., Thatcher, Thomas H., Jones, Mark G., Smart, David E., Mahajan, Sumeet, Alzetani, Aiman, Havelock, Tom, Maher, Toby M., Molyneaux, Philip L., Thorley, Andrew J., Tetley, Teresa D., Warner, Jane A., Packham, Graham, Ganesan, A., Skipp, Paul J., Marshall, Benjamin J., Richeldi, Luca, Sime, Patricia J., O'Reilly, Katherine M.A., Davies, Donna E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564721/
https://www.ncbi.nlm.nih.gov/pubmed/28467787
http://dx.doi.org/10.18632/oncotarget.17114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564721/
https://www.ncbi.nlm.nih.gov/pubmed/28467787
http://dx.doi.org/10.18632/oncotarget.17114

Ejemplares similares